Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aytu BioPharma, Inc.

Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property
Tickers AYTU
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma to Participate in the 34th Annual Roth Conference
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Completes $15 Million Debt Refinancing
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers AYTU
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers AYTU
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers AYTU
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property
Tickers AYTU
Aytu BioPharma Reports First Quarter 2022 Financial Results
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers AYTU
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers AYTU
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers AYTU
Aytu BioPharma to Present at Upcoming September Investor Conferences
From Aytu BioPharma, Inc.
Via AccessWire
Tickers AYTU
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers AYTU
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers AYTU
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.